Lipid nanoparticles for oral delivery of nucleic acids for treating inflammatory bowel disease

NanomedicineVol. 17, No. 21 EditorialLipid nanoparticles for oral delivery of nucleic acids for treating inflammatory bowel diseaseChunhua Yang, Gianfranco Alpini, Shannon Glaser & Didier MerlinChunhua Yang *Author for correspondence: E-mail Address: cyang16@gsu.eduhttps://orcid.org/0000-0003-0805-1008Institute for Biomedical Sciences, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30303, USAResearch, Atlanta Veterans Affairs Medical Center, Decatur, GA 30302, USA, Gianfranco AlpiniDepartment of Medicine, Division of Gastroenterology & Hepatology, Indiana University School of Medicine, Indianapolis, IN 46220, USAResearch, Richard L. Roudebush VA Medical Center, Indianapolis, IN 46202, USA, Shannon GlaserDepartment of Medical Physiology, Texas A&M University School of Medicine, Bryan, TX 77807, USA & Didier MerlinInstitute for Biomedical Sciences, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30303, USAResearch, Atlanta Veterans Affairs Medical Center, Decatur, GA 30302, USAPublished Online:1 Nov 2022https://doi.org/10.2217/nnm-2022-0222AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: Crohn's diseasegene therapyplant-derived lipid nanoparticlessolid lipid nanoparticlestargeted drug deliveryulcerative colitisPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Zhang W, Michalowski CB, Beloqui A. Oral delivery of biologics in inflammatory bowel disease treatment. Front. Bioeng. Biotechnol. 9, 675194 (2021). • A review article that covers broad topics for oral biologics delivery.Crossref, Medline, Google Scholar2. Yang C, Long D, Sung J, Alghoul Z, Merlin D. Orally administered natural lipid nanoparticle-loaded 6-shogaol shapes the anti-inflammatory microbiota and metabolome. Pharmaceutics 13(9), 1355 (2021).Crossref, Medline, CAS, Google Scholar3. Serpe L, Canaparo R, Daperno M et al. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur. J. Pharm. Sci. 39(5), 428–436 (2010).Crossref, Medline, CAS, Google Scholar4. Ball RL, Bajaj P, Whitehead KA. Oral delivery of siRNA lipid nanoparticles: fate in the GI tract. Sci. Rep. 8(1), 2178 (2018). •• A proof-of-principle study for oral siRNA delivery.Crossref, Medline, Google Scholar5. Basha SK, Dhandayuthabani R, Muzammil MS, Kumari VS. Solid lipid nanoparticles for oral drug delivery. Mater. Today Proc. 36, 313–324 (2021).Crossref, CAS, Google Scholar6. Eder P, Zielinska A, Karczewski J, Dobrowolska A, Slomski R, Souto EB. How could nanobiotechnology improve treatment outcomes of anti-TNF-alpha therapy in inflammatory bowel disease? Current knowledge, future directions. J. Nanobiotechnol. 19(1), 346 (2021).Crossref, Medline, CAS, Google Scholar7. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25(7), 1467–1475 (2017).Crossref, Medline, CAS, Google Scholar8. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles – from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 15(11), 16982–17015 (2021).Crossref, Medline, CAS, Google Scholar9. Yang C, Sung J, Long D, Alghoul Z, Merlin D. Prevention of ulcerative colitis by autologous metabolite transfer from colitogenic microbiota treated with lipid nanoparticles encapsulating an anti-inflammatory drug candidate. Pharmaceutics 14(6), 1233 (2022).Crossref, Medline, CAS, Google Scholar10. Gomez-Aguado I, Rodriguez-Castejon J, Vicente-Pascual M, Rodriguez-Gascon A, Pozo-Rodriguez AD, Solinis Aspiazu MA. Nucleic acid delivery by solid lipid nanoparticles containing switchable lipids: plasmid DNA vs. messenger RNA. Molecules 25(24), 5995 (2020).Crossref, Medline, CAS, Google Scholar11. Yang C, Merlin D. Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives. Int. J. Nanomed. 14, 8875–8889 (2019).Crossref, Medline, CAS, Google Scholar12. Carrillo C, Sanchez-Hernandez N, Garcia-Montoya E et al. DNA delivery via cationic solid lipid nanoparticles (SLNs). Eur. J. Pharm. Sci. 49(2), 157–165 (2013).Crossref, Medline, CAS, Google Scholar13. de Jesus MB, Zuhorn IS. Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms. J. Control. Release 201, 1–13 (2015).Crossref, Medline, CAS, Google Scholar14. Ezzati Nazhad Dolatabadi J, Valizadeh H, Hamishehkar H. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv. Pharm. Bull. 5(2), 151–159 (2015).Crossref, Medline, Google Scholar15. Yang C, Zhang M, Merlin D. Advances in plant-derived edible nanoparticle-based lipid nano-drug delivery systems as therapeutic nanomedicines. J. Mater. Chem. B 6(9), 1312–1321 (2018).Crossref, Medline, CAS, Google Scholar16. Zhang M, Wang X, Han MK, Collins JF, Merlin D. Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine (Lond.) 12(16), 1927–1943 (2017).Link, CAS, Google Scholar17. Yang C, Merlin D. Can naturally occurring nanoparticle-based targeted drug delivery effectively treat inflammatory bowel disease? Expert. Opin. Drug Deliv. 17(1), 1–4 (2020).Crossref, Medline, Google Scholar18. Sung J, Alghoul Z, Long D, Yang C, Merlin D. Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: a novel therapeutic solution to treat ulcerative colitis. Biomaterials 288, 121707 (2022). •• This paper introduced a well-defined new lipid nanoparticle platform for oral mRNA delivery.Crossref, Medline, CAS, Google Scholar19. Veiga N, Goldsmith M, Granot Y et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat. Commun. 9(1), 4493 (2018).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 17, No. 21 Follow us on social media for the latest updates Metrics Downloaded 57 times History Received 29 August 2022 Accepted 11 October 2022 Published online 1 November 2022 Published in print September 2022 Information© 2022 Future Medicine LtdKeywordsCrohn's diseasegene therapyplant-derived lipid nanoparticlessolid lipid nanoparticlestargeted drug deliveryulcerative colitisAuthor contributionsConceptualization: C Yang and D Merlin; writing – original draft preparation: C Yang; writing – review and editing: G Alpini, S Glaser and D Merlin; all authors have read and agreed to the version of the manuscript.Financial & competing interests disclosureThis research was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), grant nos. RO1DK107739 (D Merlin), RO1DK116306 (D Merlin) and R01DK132891 (G Alpini and S Glaser), and Department of Veterans Affairs (BX002526, D Merlin). A portion of this work was supported by the Hickam Endowed Chair, Gastroenterology, Medicine, Indiana University grant, and the Indiana University Health–Indiana University School of Medicine Strategic Research Initiative grant to G Alpini. D Merlin and G Alpini are recipients of a Senior Research Career Scientist Award (BX004476) from the Department of Veterans Affairs. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download